tradmap

DBD Financials Diebold Nixdorf, Inc

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has declined 0.5% per year over the past 5 years.
  • Operating margin has expanded, at 6.4% in the latest year.

Financial health

  • Total debt ($939M) exceeds cash ($387M); net debt is $551M.
  • Total debt has grown slower than revenue (-28.4% vs -0.5% per year).
  • Operating income covered interest expense 2.8× in the latest year.
  • Total debt is 2.5× EBITDA.
Revenue & net income
-$581M $2B $5B $0 2010 2012 2014 2016 2018 2020 2022 2025
RevenueNet income
Margins (gross / operating / net)
-17% 5% 27% 0% 2010 2012 2014 2016 2018 2020 2022 2025
GrossOperatingNet
Return on equity & assets (ROE / ROA)
-54% 150% 355% 0% 2010 2012 2014 2016 2018 2020 2022 2025
ROEROA
Free cash flow (CFO − capex)
$0 $111M $222M 2010 2012 2014 2016 2018 2020 2022 2025
Free cash flow
Cash vs total debt
$0 $1B $3B 2010 2012 2014 2016 2018 2020 2022 2025
CashTotal debt
Cash flow: operating / investing / financing
-$561M $160M $881M $0 2010 2012 2014 2016 2018 2020 2022 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MROEROAFCFTotal debtCash
2025 $3.8B $95M 25.3% 6.4% 8.6% 2.5% $939M $387M
2024 $3.8B -$17M 24.5% 4.9% -1.8% -0.5% $927M $311M
2022 $3.5B -$581M 21.9% -6.1% 42.1% -19.0% $2.6B $319M
2021 $3.9B -$79M 26.7% 3.5% 9.3% -2.2% $389M
2020 $3.9B -$269M 26.5% 0.6% 32.5% -7.4% $325M
2019 $4.4B -$341M 24.2% -0.6% 64.4% -9.0% $281M
2018 $4.6B -$531M 19.6% -7.1% 355.0% -12.4% $458M
2017 $4.6B -$242M 21.7% -2.0% -54.2% -4.6% $543M
2016 $3.3B -$42M 21.5% -5.1% -7.1% -0.8% $653M
2015 $74M 17.9% 3.3% $314M
2014 $114M 21.5% 4.9%
2013 -$182M -30.4% -8.3%
2012 $74M 9.3% 2.8%
2011 $144M 17.7% 5.7%
2010 -$20M -2.1% -0.8% $222M

Valuation over time

How the market has priced DBD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 15.3 30.5 Mar '23 Nov '23 May '24 Nov '24 May '25 Nov '25 May '26
P/E
Price / sales (P/S)
0.0 0.4 0.8 Mar '23 Nov '23 May '24 Nov '24 May '25 Nov '25 May '26
P/S

Frequently asked questions

Is DBD growing its revenue and profit?

Over the past 5 years, Diebold Nixdorf, Inc's revenue has declined 0.5% per year. These are computed facts, not advice.

How much debt does DBD have?

As of FY2025, Diebold Nixdorf, Inc reported $939M of total debt against $387M of cash; operating income covered interest expense 2.8×.

What is DBD's profit margin?

In FY2025, gross margin was 25.3%, operating margin 6.4%, and net margin 2.5%.

What is DBD's P/E ratio?

As of Sep '26, Diebold Nixdorf, Inc traded at a price-to-earnings ratio of about 24.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.